Rosuvastatin protects against podocyte apoptosis in vitro

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 404-412

  Cormack Aboud, Fionnuala C ^a   Brinkkoetter, Paul T ^a   Pippin, Jeffrey W ^a   Shankland, Stuart J ^a   Durvasula, Raghu V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; p21; Podocyte; Statins

Indexed keywords

DOXORUBICIN; P21 ACTIVATED KINASE; PUROMYCIN AMINONUCLEOSIDE; ROSUVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GLOMERULOSCLEROSIS; IN VITRO STUDY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, KNOCKOUT; PODOCYTES; PROTEINURIA; PUROMYCIN AMINONUCLEOSIDE; PYRIMIDINES; RECOMBINANT PROTEINS; SULFONAMIDES; TRANSDUCTION, GENETIC;

EID: 58449110318     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn528     Document Type: Article

References (42)

1. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015
2. Kriz W, Elger M, Nagata M et al. The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl 1994; 45: S64-S72
3. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697
4. Kriz W, Hosser H, Hahnel B et al. From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Nephrol Dial Transplant 1998; 13: 2781-2798
5. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348
6. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147
7. Susztak K, Raff A, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233
8. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734
9. Bianchi S, Bigazzi R, Caiazza A et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570
10. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16(Suppl 1): S11-S17
11. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-24
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269
13. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016
14. Tonelli M, Moye L, Sacks FM et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-1613
15. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: S2-S5
16. Jat PS, Noble MD, Ataliotis P et al. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991; 88: 5096-5100
17. Mundel P, Reiser J, Kriz W. Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997; 8: 697-705
18. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258
19. Shankland SJ, Pippin JW, Reiser J et al. Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36
20. Wada T, Pippin JW, Terada Y et al. The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005; 68: 1618-1629
21. Martin PD, Dane AL, Nwose OM et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002; 42: 1116-1121
22. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125
23. Hommel E, Andersen P, Gall MA et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447-451
24. Nielsen S, Schmitz O, Moller N et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079-1086
25. Danesh FR, Sadeghi MM, Amro N et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002; 99: 8301-8305
26. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000; 11: 80-87
27. Kaneko R, Tsuji N, Asanuma K et al. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 2007; 282: 19273-19281
28. Marz P, Otten U, Miserez AR. Statins induce differentiation and cell death in neurons and astroglia. Glia 2007; 55: 1-12
29. Tsujimoto A, Takemura G, Mikami A et al. A therapeutic dose of the lipophilic statin pitavastatin enhances oxidant-induced apoptosis in human vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 48: 160-165
30. Liang SL, Liu H, Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 2006; 177: 651-656
31. Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 1379-1383
32. Bussolati B, Deregibus MC, Fonsato V et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 2005; 16: 1936-1947
33. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006; 17: 754-764
34. Whaley-Connell A, Habibi J, Nistala R et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008; 51: 474-480
35. Whaley-Connell A, DeMarco VG, Lastra G et al. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 2008; 28: 67-75
36. Gu L, Ni Z, Qian J et al. Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signalling events. Nephron Exp Nephrol 2007; 106: e1-e10
37. Agell N, Jaumot M, Rodriguez-Vilarrupla A et al. The diverging roles of calmodulin and PKC in the regulation of p21 intracellular localization. Cell Cycle 2006; 5: 3-6
38. Child ES, Mann DJ. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 2006; 5: 1313-1319
39. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65-70
40. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649
41. Suzuki A, Tsutomi Y, Akahane K et al. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-939
42. Asada M, Yamada T, Ichijo H et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18: 1223-1234